Drugmakers and patient advocacy groups are pushing back against a federal proposal to cut off most Medicare payments for a new drug from Biogen Inc. to treat Alzheimer’s, called Aduhelm. The Centers for Medicare and Medicaid Services last month proposed to limit coverage of the drug to patients enrolled in clinical trials which are sanctioned by the agency. The proposal would apply to similar drugs still in development and not yet approved that work by reducing amyloid protein in the brain. The high cost of the drug and questions over its efficacy are behind the decision of the Centers for Medicare and Medicaid Services.
